Two years into the pandemic that has killed millions and shaken the global economy, the world still lacks a unified effort to detect and fight future outbreaks using genetic tools, said Illumina Inc. Chief Executive Officer Francis deSouza.
How genomics provided critical answers—and in record time—to transform outcomes for a newborn and his family
In June 2019, Christina and Daniel Kettler were barely home from the hospital with their newborn son when they received an urgent phone call. They needed to rush back immediately: A routine screening, called the heel stick test, had revealed that Fitz, their firstborn baby, had Severe Combined Immunodeficiency (SCID). SCID is a rare condition also known as “bubble boy disease.”
SAN DIEGO, April 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of John Frank as the Company's Chief Public Affairs Officer (CPAO). Frank joins Illumina on April 18 from Microsoft Corporation; he will report to Chief Executive Officer Francis deSouza.
Regional Solution Center in São Paulo, Brazil will enable customer access to next-generation sequencing training and expertise to improve patient outcomes
SAN DIEGO, April 13, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of its new state-of-the-art Solution Center in São Paulo, Brazil. The choice to bring the facility to Brazil reflects an increasing demand for and interest in clinical genomics, as well as Illumina's longstanding commitment to expanding global access to genomics in Latin America.
Report highlights contributions of genomics to advances in public health and overall health of our planet
SAN DIEGO, April 7, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social Responsibility (CSR) Report, highlighting the company's 2021 environmental, social, and governance (ESG) program and commitment to human health. The report details Illumina's role as a champion for patients, communities, people, and the planet.
An Illumina iConserve project is mapping genetic diversity to identify where confiscated gorillas come from and boost survival rates
Dr. Magdalena Bermejo is calling from a 50-square-meter house deep in a rainforest in the Republic of Congo. Her home and research station on the southwestern border of Odzala-Kokoua National Park, part of the Sabine Plattner African Charities (SPAC) World-Class Field Station Network (WCFS-Network), is one of the few places where large-scale studies of high-density western lowland gorilla populations are still possible.
Which infectious disease kills more people in the world than any other? It mutates, mostly impacts your lungs, very contagious in a close household setting, can be asymptomatic and hard to eradicate. Did you want to say COVID?
Biobot Analytics is using wastewater data to predict COVID surges and other outbreaks
Whether we realize it or not, we leave clues to our health every time we use the bathroom.
The excretions we flush down the drain without a second thought offer a treasure trove of data and community health insight to Biobot Analytics. Biobot is the first company in the world to commercialize data from sewage. What we eat, the pathogens we harbor, and the drugs we use all end up in wastewater, and ultimately, that sewage contains a wealth of information about a community’s health.